Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.51 |
| ▸ | CTSL | P07711 | 5/20 | 0.50 |
| ▸ | CTSS | P25774 | 5/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16333600 | 1.00 | CTSK (0.51) | CTSKCTSLCTSSCTSBCYP3A4 | |
| SCHEMBL13820299 | 0.88 | CA1 (0.45) | CTSKCTSLCTSSCTSBCYP3A4 | |
| SCHEMBL10241666 | 0.88 | CA1 (0.45) | CTSKCTSLCTSSCTSBCYP3A4 | |
| SCHEMBL16301415 | 0.82 | CA1 (0.49) | CTSKCTSLCTSSCTSBCYP3A4 | |
| SCHEMBL10241658 | 0.80 | CA1 (0.50) | CTSKCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL11636918 | 0.79 | CA1 (0.63) | CTSKCTSLCTSSCYP3A4RAB9A | |
| SCHEMBL15879567 | 0.78 | TRPM8 (0.60) | CTSKCTSLCTSSCTSBCYP3A4 | |
| SCHEMBL5192939 | 0.78 | TRPM8 (0.60) | CTSKCTSLCTSSCTSBCYP3A4 | |
| SCHEMBL10241671 | 0.78 | CTSK (0.58) | CTSKCTSLCTSSCTSB | |
| SCHEMBL2678260 | 0.78 | CTSL (0.70) | CTSKCTSLCTSSCTSBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289471-A1 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289471-A1 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8173840-B2 | Compounds with high therapeutic index | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173840-B2 | Compounds with high therapeutic index | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2007089745-A2 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R & D HOLDINGS, LLC (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289471-A1 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | IL4I1, SLC7A1, GOT1 | CTSK 903/4885CTSL 245/4885CTSS 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.